More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$34.12B
EPS
10.98
P/E ratio
22
Price to sales
5.72
Dividend yield
1.088%
Beta
0.770447
Previous close
$237.85
Today's open
$236.38
Day's range
$236.14 - $246.14
52 week range
$180.27 - $277.67
show more
CEO
Michael J. Farrell
Employees
11370
Headquarters
San Diego, CA
Exchange
New York Stock Exchange
Shares outstanding
140657071
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Top 50 High-Quality Dividend Growth Stocks For November 2026
I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; 27 appear undervalued relative to historical free cash flow. ResMed leads with 41.60% estimated return potential; MarketAxess rose to fifth at 28.50% after a valuation upgrade and higher fair value estimate.
Seeking Alpha • Nov 14, 2026

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).
NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of ResMed Inc. (NYSE: RMD) concerning possible breaches of fiduciary duties. If you are a current shareholder of RMD, you can request additional information here: https://zlk.com/cases/resmed-inc-investigation-rmd or contact Joseph E.
PRNewsWire • Nov 10, 2026

Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
Barrons • Nov 5, 2026

Top 10 High Growth Dividend Stocks For November 2026
I present 10 high-quality dividend growth stocks with strong total return potential, screened for robust fundamentals and attractive valuations as of November 2026. Key criteria include Investment Score ≥70, future return potential ≥12%, consistent 7%+ dividend growth, and payout ratios below 100%. Top picks such as RMD, NTES, and NVDA offer compelling upside, with future return estimates driven by EPS growth, yield, and potential valuation mean reversion.
Seeking Alpha • Nov 5, 2026

ResMed: 3 Key Takeaways for Long-Term Investors
ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.
The Motley Fool • Nov 2, 2026

What ResMed (RMD) Said on Its Q1 Earnings Call
ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earnings per share rose 14% to $2.91.
MarketBeat • Oct 30, 2026

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
Zacks Investment Research • Oct 30, 2026

ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Oct 30, 2026

ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
GlobeNewsWire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ResMed Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.